This report covers data from 2023 and 2024 with forecasts through 2027.
All sources of EPA and/or DHA in six finished product applications — dietary supplements, pharmaceuticals, food and beverages, pet nutrition, infant formula and clinical nutrition/medical foods — are included, with details in 11 different geographic regions.
The report also provides colour commentary on developments that impacted market dynamics during the last year, which proved to be a recovery year after the supply chain challenges in 2023.
“2024 was a recovery year after one of the strongest El Niño events on record disrupted the supply chain for Peruvian anchovy oils, the main raw source, in 2022/2023,” GOED states in the report.
“The resulting supply shortages and high prices had a profound effect on the industry and this only started resolving in the second half of the year.”
For 2024, the total global volume of omega-3 ingredients was 131,183 metric tons, a 2.5% increase compared with 2023, although the value increased 10.2% to $2379.7 million.
Pet nutrition and dietary supplements continue to be drivers of growth, as are emerging geographic markets.
The report also examines the factors that may influence future category growth, including tariffs, fishery developments, pricing dynamics, regulatory requirements, pharmaceutical approvals and new scientific findings.
Owing to GOED’s intimate knowledge of the category and its access to proprietary sales data from member companies, the report is considered the most accurate and comprehensive report available on the global EPA and DHA industry.